At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Bomedemstatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV)
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)·interventional·Posted Sep 28, 2022·Updated May 7, 2026
In Brief
A Phase 2 clinical trial evaluating Bomedemstat for Polycythemia Vera. Completed, enrolled 20 participants across 17 sites in 3 countries.
Detailed Summary
This study will evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of the orally administered lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat, in participants with polycythemia vera (PV). At Week 36 of dosing, participants will be assessed for eligibility to receive additional treatment through Week 52. Participants deriving clinical benefit and safely tolerating bomedemstat will qualify for continued treatment at the Investigator's discretion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycythemia Vera
CountriesAustralia, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartSep 2023
Primary CompletionMar 2025
Study CompletionJul 2025
TodayJul 2026
First PostedSep 28, 2022
Enrollment StartSep 7, 2023
Primary CompletionMar 24, 2025
Study CompletionJul 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.8 years ago
Interventions
Bomedemstatdrug
Oral capsule